BioSpecifics has strong, long-term patent protection for injectable collagenase and owns, co-owns or controls patents and patent applications for injectable collagenase to treat:

  • Dupuytren's contracture
  • Peyronie's disease
  • Frozen shoulder syndrome
  • Removal of adipose tissue
  • Others


Long-term patent protection for CCH

Dupuytren's Contracture

  • Biologic Exclusivity until 2022
  • Drug product composition and manufacturing patent until 2028
Peyronie's Disease
  • Orphan Drug protection in U.S until 2020
  • Drug product composition and manufacturing patent until 2028
Uterine Fibroids
  • Method of use patent until 2034
Patents and Patent Applications
  • Owned, co-owned or controlled by BioSpecifics for injectable collagenase to treat Dupuytren's contracture, Peyronie's disease, removal of adipose tissue and frozen shoulder syndrome and others
  • Royalties through 2028
The Company also has additional patents pending and intends to seek patent protection whenever available for any products or product candidates and related technology the Company develops or acquires in the future.